XML 13 R2.htm IDEA: XBRL DOCUMENT
v3.23.1

Pay vs Performance Disclosure - USD ($) | 12 Months Ended |  |  |  |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | Oct. 01, 2022 | Jul. 01, 2022 | Apr. 01, 2022 | Oct. 01, 2021 | Jul. 01, 2021 | Apr. 01, 2021 | Oct. 01, 2020 | Jul. 01, 2020 | Apr. 01, 2020 | Dec. 31, 2019
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance [Table Text Block] | PAY VERSUS PERFORMANCE The Company’s compensation objectives and philosophy, which are discussed further above, are designed to reward the contributions of its NEOs to the Company’s financial performance and provide compensation which is sufficient to attract and retain individuals who are motivated to contribute to the Company’s financial performance. To achieve these goals, the Company has implemented incentive plans which tie a significant portion of each NEO’s compensation to pre-determined financial goals. For the year ended December 31, 2022, the most important financial performance measures used by the Company to link executive compensation actually paid to the Company’s financial performance was After-tax Operating Results. The following table summarizes the executive compensation earned by the Company’s PEO and other NEOs, the executive compensation actually paid to the Company’s PEO and other NEOs, and certain financial performance measures of the Company for the years ended December 31, 2022, 2021, and 2020.
Year(1) | ​ | ​ | Summary Compensation Table Total for PEO(1) ($) | ​ | ​ | Compensation Actually Paid to PEO(5) ($) | ​ | ​ | Average Summary Compensation Table Total for non-PEO NEOs(1) ($) | ​ | ​ | Average Compensation Actually Paid to non-PEO NEOs(5) ($) | ​ | ​ | Value of Initial Fixed $100 Investmestment Based on | ​ | ​ | Net Income(2) ($) | ​ | ​ | Operating Results(3) ($)
​ | Total Shareholder Return ($) | ​ | ​ | Peer Group Total Shareholder Return(4) ($) | ​
2022 | ​ | ​ | 2,408,584 | ​ | ​ | 1,859,559 | ​ | ​ | 1,122,465 | ​ | ​ | 920,090 | ​ | ​ | 105 | ​ | ​ | 111 | ​ | ​ | 43,407,000 | ​ | ​ | 35,034,000
2021 | ​ | ​ | 4,143,576 | ​ | ​ | 3,275,545 | ​ | ​ | 1,454,841 | ​ | ​ | 1,110,753 | ​ | ​ | 84 | ​ | ​ | 135 | ​ | ​ | 57,924,000 | ​ | ​ | 43,732,000
2020 | ​ | ​ | 2,961,147 | ​ | ​ | 2,446,657 | ​ | ​ | 1,056,375 | ​ | ​ | 829,949 | ​ | ​ | 71 | ​ | ​ | 130 | ​ | ​ | 52,491,000 | ​ | ​ | 38,435,000
(1) | The PEO is Christopher J. Reading for each of the years presented. The non-PEO NEOs are Carey P. Hendrickson, Eric J. Williams, Graham D. Reeve, and Richard Binstein for 2022, Carey P. Hendrickson, Eric J. Williams, Glenn D. McDowell, and Graham D. Reeve for 2021 and Carey P. Hendrickson, Lawrance W. MacAfee, Glenn D. McDowell, and Graham D. Reeve for 2020.
(2) | Net income includes earnings attributable to both controlling and non-controlling interests.
(3) | Operating Results, a non-GAAP measure, for the years ended December 31, 2022, 2021 and 2020 equals net income attributable to our diluted shareholders per the consolidated statements of income, adjusted for unusual, non-recurring and non-operational charges including: revaluation of redeemable non-controlling interest, goodwill impairment, changes in fair value of contingent consideration, expenses related to executive officer transitions, settlement of a legal matter, and any applicable allocations to non-controlling interests of such items, all net of taxes. In addition, Operating Results for the year ended December 31, 2020, excludes clinic closure costs and the gain on sale of partnership interests and clinics mainly resulting from the COVID-19 pandemic. A detailed calculation of Operating Results can be found in Part II, Item 7 of the Company's Annual Report on Form 10-K for the years ended December 31, 2022, and December 31, 2021.
(4) | The Total Shareholder Return assumes that $100 was invested in our common stock and the common stock on each of the companies listed on The NYSE Heathcare Index (the Company’s Peer Group), on December 31, 2019 and that any dividends were reinvested.
(5) | For a computation of compensation actually paid to PEO and average compensation actually paid to non-PEO NEOs, please refer to the subsequent table.
The following table outlines the adjustments made to the compensation earned by the Company’s PEO and other NEOs, as presented in the Summary Compensation Table on page 30, to derive the compensation actually paid to the Company’s PEO and other NEOs.
Year | ​ | ​ |  | ​ | ​ | Adjustments
​ | Summary Compensation Table Total ($) | ​ | ​ | Less: Reported Value of Stock Awards ($)(1) | ​ | ​ | Plus: Year End Fair Value of Restricted Stock Awards Granted During the Year ($)(2)(3) | ​ | ​ | Plus: Change in Fair Value of Outstanding and Unvested Restricted Stock Awards ($)(2)(3) | ​ | ​ | Plus: Changes in Fair Value of Restricted Stock in Prior Years that Vested During the Year Year ($)(2)(3) | ​ | ​ | Dividends paid on Unvested Restricted Stock Awards During the Fiscal Year ($)(4) | ​ | ​ | Compensation Actually Paid ($)
PEO | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |
2022 | ​ | ​ | 2,408,584 | ​ | ​ | 1,016,800 | ​ | ​ | 810,300 | ​ | ​ | (411,395) | ​ | ​ | 22,404 | ​ | ​ | 46,466 | ​ | ​ | 1,859,559
2021 | ​ | ​ | 4,143,576 | ​ | ​ | 2,120,100 | ​ | ​ | 1,911,000 | ​ | ​ | (613,844) | ​ | ​ | (81,371) | ​ | ​ | 36,284 | ​ | ​ | 3,275,545
2020 | ​ | ​ | 2,961,147 | ​ | ​ | 1,533,056 | ​ | ​ | 1,346,800 | ​ | ​ | 180,251 | ​ | ​ | (518,261) | ​ | ​ | 9,776 | ​ | ​ | 2,446,657
Non-PEO | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |
2022 | ​ | ​ | 1,122,465 | ​ | ​ | 444,850 | ​ | ​ | 354,506 | ​ | ​ | (132,671) | ​ | ​ | 5,768 | ​ | ​ | 14,872 | ​ | ​ | 920,090
2021 | ​ | ​ | 1,454,841 | ​ | ​ | 706,539 | ​ | ​ | 537,469 | ​ | ​ | (157,849) | ​ | ​ | (26,493) | ​ | ​ | 9,325 | ​ | ​ | 1,110,753
2020 | ​ | ​ | 1,056,375 | ​ | ​ | 484,122 | ​ | ​ | 447,571 | ​ | ​ | 63,051 | ​ | ​ | (256,345) | ​ | ​ | 3,419 | ​ | ​ | 829,949
(1) | Represents the grant date fair value of restricted stock awards earned and as reported in the “Stock Awards” column of the Summary Compensation Table for each applicable year. These shares were issued in March of the succeeding year.
(2) | Adjustments are equal to (i) the year-end fair value of restricted stock awards granted during the applicable year that are earned but not issued and therefore deemed outstanding and unvested as of the end of the year, (ii) the amount of the change in fair value as of the end of the applicable year (from the end of the prior fiscal year) of any restricted stock awards granted in prior years that are outstanding and unvested as of the end of the applicable year, and (iii) for restricted stock awards granted in prior years that vest in the applicable year, an amount equal to the change in fair value as of the vesting date (from the end of the prior fiscal year).
(3) | Restricted stock awards are valued using the market price of our stock. The closing market price of our stock was $81.03, $95.55, $120.25, and $114.35 as of December 31, 2022, 2021, 2020, and 2019, respectively. The closing market price of our stock when the PEO and other NEOs’ restricted stock awards vested was $95.55 on January 1, 2022, $103.76 on April 1, 2022, $112.30 on July 1, 2022, $760.02 on October 1, 2022, $120.25 on January 1, 2021, $110.21 on April 1, 2021, $119.34 on July 1, 2021, $111.55 on October 1, 2021, $114.35 on January 1, 2020, $59.00 on April 1, 2020, $81.02 on July 1, 2020 and $86.88 on October 1, 2020.
(4) | Includes dividends paid and declared on outstanding and unvested shares as of December 31, 2022, 2021 and 2020. Dividends declared per common share were $1.64, $1.46, and $0.32 for the fiscal years ended December 31, 2022, 2021 and 2020, respectively.
Company Selected Measure Name | Operating Results |  |  |  |  |  |  |  |  |  |  |  |
Named Executive Officers, Footnote [Text Block] |
(1) | The PEO is Christopher J. Reading for each of the years presented. The non-PEO NEOs are Carey P. Hendrickson, Eric J. Williams, Graham D. Reeve, and Richard Binstein for 2022, Carey P. Hendrickson, Eric J. Williams, Glenn D. McDowell, and Graham D. Reeve for 2021 and Carey P. Hendrickson, Lawrance W. MacAfee, Glenn D. McDowell, and Graham D. Reeve for 2020.
Peer Group Issuers, Footnote [Text Block] |
(4) | The Total Shareholder Return assumes that $100 was invested in our common stock and the common stock on each of the companies listed on The NYSE Heathcare Index (the Company’s Peer Group), on December 31, 2019 and that any dividends were reinvested.
PEO Total Compensation Amount | $ 2,408,584 | $ 4,143,576 | $ 2,961,147 |  |  |  |  |  |  |  |  |  |
PEO Actually Paid Compensation Amount | $ 1,859,559 | 3,275,545 | 2,446,657 |  |  |  |  |  |  |  |  |  |
Adjustment To PEO Compensation, Footnote [Text Block] |
(5) | For a computation of compensation actually paid to PEO and average compensation actually paid to non-PEO NEOs, please refer to the subsequent table.
The following table outlines the adjustments made to the compensation earned by the Company’s PEO and other NEOs, as presented in the Summary Compensation Table on page 30, to derive the compensation actually paid to the Company’s PEO and other NEOs.
Year | ​ | ​ |  | ​ | ​ | Adjustments
​ | Summary Compensation Table Total ($) | ​ | ​ | Less: Reported Value of Stock Awards ($)(1) | ​ | ​ | Plus: Year End Fair Value of Restricted Stock Awards Granted During the Year ($)(2)(3) | ​ | ​ | Plus: Change in Fair Value of Outstanding and Unvested Restricted Stock Awards ($)(2)(3) | ​ | ​ | Plus: Changes in Fair Value of Restricted Stock in Prior Years that Vested During the Year Year ($)(2)(3) | ​ | ​ | Dividends paid on Unvested Restricted Stock Awards During the Fiscal Year ($)(4) | ​ | ​ | Compensation Actually Paid ($)
PEO | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |
2022 | ​ | ​ | 2,408,584 | ​ | ​ | 1,016,800 | ​ | ​ | 810,300 | ​ | ​ | (411,395) | ​ | ​ | 22,404 | ​ | ​ | 46,466 | ​ | ​ | 1,859,559
2021 | ​ | ​ | 4,143,576 | ​ | ​ | 2,120,100 | ​ | ​ | 1,911,000 | ​ | ​ | (613,844) | ​ | ​ | (81,371) | ​ | ​ | 36,284 | ​ | ​ | 3,275,545
2020 | ​ | ​ | 2,961,147 | ​ | ​ | 1,533,056 | ​ | ​ | 1,346,800 | ​ | ​ | 180,251 | ​ | ​ | (518,261) | ​ | ​ | 9,776 | ​ | ​ | 2,446,657
Non-PEO | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |
2022 | ​ | ​ | 1,122,465 | ​ | ​ | 444,850 | ​ | ​ | 354,506 | ​ | ​ | (132,671) | ​ | ​ | 5,768 | ​ | ​ | 14,872 | ​ | ​ | 920,090
2021 | ​ | ​ | 1,454,841 | ​ | ​ | 706,539 | ​ | ​ | 537,469 | ​ | ​ | (157,849) | ​ | ​ | (26,493) | ​ | ​ | 9,325 | ​ | ​ | 1,110,753
2020 | ​ | ​ | 1,056,375 | ​ | ​ | 484,122 | ​ | ​ | 447,571 | ​ | ​ | 63,051 | ​ | ​ | (256,345) | ​ | ​ | 3,419 | ​ | ​ | 829,949
(1) | Represents the grant date fair value of restricted stock awards earned and as reported in the “Stock Awards” column of the Summary Compensation Table for each applicable year. These shares were issued in March of the succeeding year.
(2) | Adjustments are equal to (i) the year-end fair value of restricted stock awards granted during the applicable year that are earned but not issued and therefore deemed outstanding and unvested as of the end of the year, (ii) the amount of the change in fair value as of the end of the applicable year (from the end of the prior fiscal year) of any restricted stock awards granted in prior years that are outstanding and unvested as of the end of the applicable year, and (iii) for restricted stock awards granted in prior years that vest in the applicable year, an amount equal to the change in fair value as of the vesting date (from the end of the prior fiscal year).
(3) | Restricted stock awards are valued using the market price of our stock. The closing market price of our stock was $81.03, $95.55, $120.25, and $114.35 as of December 31, 2022, 2021, 2020, and 2019, respectively. The closing market price of our stock when the PEO and other NEOs’ restricted stock awards vested was $95.55 on January 1, 2022, $103.76 on April 1, 2022, $112.30 on July 1, 2022, $760.02 on October 1, 2022, $120.25 on January 1, 2021, $110.21 on April 1, 2021, $119.34 on July 1, 2021, $111.55 on October 1, 2021, $114.35 on January 1, 2020, $59.00 on April 1, 2020, $81.02 on July 1, 2020 and $86.88 on October 1, 2020.
(4) | Includes dividends paid and declared on outstanding and unvested shares as of December 31, 2022, 2021 and 2020. Dividends declared per common share were $1.64, $1.46, and $0.32 for the fiscal years ended December 31, 2022, 2021 and 2020, respectively.
Non-PEO NEO Average Total Compensation Amount | $ 1,122,465 | 1,454,841 | 1,056,375 |  |  |  |  |  |  |  |  |  |
Non-PEO NEO Average Compensation Actually Paid Amount | $ 920,090 | 1,110,753 | 829,949 |  |  |  |  |  |  |  |  |  |
Adjustment to Non-PEO NEO Compensation Footnote [Text Block] |
(5) | For a computation of compensation actually paid to PEO and average compensation actually paid to non-PEO NEOs, please refer to the subsequent table.
The following table outlines the adjustments made to the compensation earned by the Company’s PEO and other NEOs, as presented in the Summary Compensation Table on page 30, to derive the compensation actually paid to the Company’s PEO and other NEOs.
Year | ​ | ​ |  | ​ | ​ | Adjustments
​ | Summary Compensation Table Total ($) | ​ | ​ | Less: Reported Value of Stock Awards ($)(1) | ​ | ​ | Plus: Year End Fair Value of Restricted Stock Awards Granted During the Year ($)(2)(3) | ​ | ​ | Plus: Change in Fair Value of Outstanding and Unvested Restricted Stock Awards ($)(2)(3) | ​ | ​ | Plus: Changes in Fair Value of Restricted Stock in Prior Years that Vested During the Year Year ($)(2)(3) | ​ | ​ | Dividends paid on Unvested Restricted Stock Awards During the Fiscal Year ($)(4) | ​ | ​ | Compensation Actually Paid ($)
PEO | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |
2022 | ​ | ​ | 2,408,584 | ​ | ​ | 1,016,800 | ​ | ​ | 810,300 | ​ | ​ | (411,395) | ​ | ​ | 22,404 | ​ | ​ | 46,466 | ​ | ​ | 1,859,559
2021 | ​ | ​ | 4,143,576 | ​ | ​ | 2,120,100 | ​ | ​ | 1,911,000 | ​ | ​ | (613,844) | ​ | ​ | (81,371) | ​ | ​ | 36,284 | ​ | ​ | 3,275,545
2020 | ​ | ​ | 2,961,147 | ​ | ​ | 1,533,056 | ​ | ​ | 1,346,800 | ​ | ​ | 180,251 | ​ | ​ | (518,261) | ​ | ​ | 9,776 | ​ | ​ | 2,446,657
Non-PEO | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |  | ​ | ​ |
2022 | ​ | ​ | 1,122,465 | ​ | ​ | 444,850 | ​ | ​ | 354,506 | ​ | ​ | (132,671) | ​ | ​ | 5,768 | ​ | ​ | 14,872 | ​ | ​ | 920,090
2021 | ​ | ​ | 1,454,841 | ​ | ​ | 706,539 | ​ | ​ | 537,469 | ​ | ​ | (157,849) | ​ | ​ | (26,493) | ​ | ​ | 9,325 | ​ | ​ | 1,110,753
2020 | ​ | ​ | 1,056,375 | ​ | ​ | 484,122 | ​ | ​ | 447,571 | ​ | ​ | 63,051 | ​ | ​ | (256,345) | ​ | ​ | 3,419 | ​ | ​ | 829,949
(1) | Represents the grant date fair value of restricted stock awards earned and as reported in the “Stock Awards” column of the Summary Compensation Table for each applicable year. These shares were issued in March of the succeeding year.
(2) | Adjustments are equal to (i) the year-end fair value of restricted stock awards granted during the applicable year that are earned but not issued and therefore deemed outstanding and unvested as of the end of the year, (ii) the amount of the change in fair value as of the end of the applicable year (from the end of the prior fiscal year) of any restricted stock awards granted in prior years that are outstanding and unvested as of the end of the applicable year, and (iii) for restricted stock awards granted in prior years that vest in the applicable year, an amount equal to the change in fair value as of the vesting date (from the end of the prior fiscal year).
(3) | Restricted stock awards are valued using the market price of our stock. The closing market price of our stock was $81.03, $95.55, $120.25, and $114.35 as of December 31, 2022, 2021, 2020, and 2019, respectively. The closing market price of our stock when the PEO and other NEOs’ restricted stock awards vested was $95.55 on January 1, 2022, $103.76 on April 1, 2022, $112.30 on July 1, 2022, $760.02 on October 1, 2022, $120.25 on January 1, 2021, $110.21 on April 1, 2021, $119.34 on July 1, 2021, $111.55 on October 1, 2021, $114.35 on January 1, 2020, $59.00 on April 1, 2020, $81.02 on July 1, 2020 and $86.88 on October 1, 2020.
(4) | Includes dividends paid and declared on outstanding and unvested shares as of December 31, 2022, 2021 and 2020. Dividends declared per common share were $1.64, $1.46, and $0.32 for the fiscal years ended December 31, 2022, 2021 and 2020, respectively.
Compensation Actually Paid vs. Total Shareholder Return [Text Block] | Relationship between Pay and TSR The graph below illustrates the relationship between compensation actually paid to the Company’s PEO and other NEOs, the cumulative total stockholder return (“TSR”) on $100 invested in the Company at the close of the market on December 31, 2019, with dividends being reinvested on the date paid through December 31, 2022, and the cumulative TSR of the NYSE Health Care Index. The NYSE Health Care Index TSR is calculated in a similar manner as the Company’s TSR. |  |  |  |  |  |  |  |  |  |  |  |
Compensation Actually Paid vs. Net Income [Text Block] | Relationship between Pay and Net Income The graph below illustrates the relationship between compensation actually paid to the Company’s PEO and other NEOs and the Company’s net income. |  |  |  |  |  |  |  |  |  |  |  |
Compensation Actually Paid vs. Company Selected Measure [Text Block] | Relationship between Pay and Operating Results The graph below illustrates the relationship between compensation actually paid to the Company’s PEO and other NEOs and the Company’s Operating Results. |  |  |  |  |  |  |  |  |  |  |  |
Total Shareholder Return Vs Peer Group [Text Block] | Relationship between Pay and TSR The graph below illustrates the relationship between compensation actually paid to the Company’s PEO and other NEOs, the cumulative total stockholder return (“TSR”) on $100 invested in the Company at the close of the market on December 31, 2019, with dividends being reinvested on the date paid through December 31, 2022, and the cumulative TSR of the NYSE Health Care Index. The NYSE Health Care Index TSR is calculated in a similar manner as the Company’s TSR. |  |  |  |  |  |  |  |  |  |  |  |
Tabular List [Table Text Block] | For the year ended December 31, 2022, the most important financial performance measures used by the Company to link executive compensation actually paid to the Company’s financial performance was After-tax Operating Results. |  |  |  |  |  |  |  |  |  |  |  |
Total Shareholder Return Amount | $ 105 | 84 | 71 |  |  |  |  |  |  |  |  |  |
Peer Group Total Shareholder Return Amount | 111 | 135 | 130 |  |  |  |  |  |  |  |  |  |
Net Income (Loss) | $ 43,407,000 | $ 57,924,000 | $ 52,491,000 |  |  |  |  |  |  |  |  |  |
Company Selected Measure Amount | 35,034,000 | 43,732,000 | 38,435,000 |  |  |  |  |  |  |  |  |  |
PEO Name | Christopher J. Reading | Christopher J. Reading | Christopher J. Reading |  |  |  |  |  |  |  |  |  |
Share price | $ 81.03 | $ 95.55 | $ 120.25 | $ 760.02 | $ 112.3 | $ 103.76 | $ 111.55 | $ 119.34 | $ 110.21 | $ 86.88 | $ 81.02 | $ 59 | $ 114.35
Dividends declared per common share | $ 1.64 | $ 1.46 | $ 0.32 |  |  |  |  |  |  |  |  |  |
Measure [Axis]: 1 |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |  |  |  |  |
Measure Name | Operating Results |  |  |  |  |  |  |  |  |  |  |  |
Non-GAAP Measure Description [Text Block] |
(3) | Operating Results, a non-GAAP measure, for the years ended December 31, 2022, 2021 and 2020 equals net income attributable to our diluted shareholders per the consolidated statements of income, adjusted for unusual, non-recurring and non-operational charges including: revaluation of redeemable non-controlling interest, goodwill impairment, changes in fair value of contingent consideration, expenses related to executive officer transitions, settlement of a legal matter, and any applicable allocations to non-controlling interests of such items, all net of taxes. In addition, Operating Results for the year ended December 31, 2020, excludes clinic closure costs and the gain on sale of partnership interests and clinics mainly resulting from the COVID-19 pandemic. A detailed calculation of Operating Results can be found in Part II, Item 7 of the Company's Annual Report on Form 10-K for the years ended December 31, 2022, and December 31, 2021.
PEO [Member] | Reported Value of Stock Awards [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | $ (1,016,800) | $ (2,120,100) | $ (1,533,056) |  |  |  |  |  |  |  |  |  |
PEO [Member] | Year End Fair Value of Restricted Stock Awards Granted During the Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | 810,300 | 1,911,000 | 1,346,800 |  |  |  |  |  |  |  |  |  |
PEO [Member] | Change in Fair Value of Outstanding and Unvested Restricted Stock Awards [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | (411,395) | (613,844) | 180,251 |  |  |  |  |  |  |  |  |  |
PEO [Member] | Changes in Fair Value of Restricted Stock in Prior Years that Vested During the Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | 22,404 | (81,371) | (518,261) |  |  |  |  |  |  |  |  |  |
PEO [Member] | Dividends paid on Unvested Restricted Stock Awards During the Fiscal Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | 46,466 | 36,284 | 9,776 |  |  |  |  |  |  |  |  |  |
Non-PEO NEO [Member] | Reported Value of Stock Awards [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | (444,850) | (706,539) | (484,122) |  |  |  |  |  |  |  |  |  |
Non-PEO NEO [Member] | Year End Fair Value of Restricted Stock Awards Granted During the Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | 354,506 | 537,469 | 447,571 |  |  |  |  |  |  |  |  |  |
Non-PEO NEO [Member] | Change in Fair Value of Outstanding and Unvested Restricted Stock Awards [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | (132,671) | (157,849) | 63,051 |  |  |  |  |  |  |  |  |  |
Non-PEO NEO [Member] | Changes in Fair Value of Restricted Stock in Prior Years that Vested During the Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | 5,768 | (26,493) | (256,345) |  |  |  |  |  |  |  |  |  |
Non-PEO NEO [Member] | Dividends paid on Unvested Restricted Stock Awards During the Fiscal Year [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Pay vs Performance Disclosure [Table] |  |  |  |  |  |  |  |  |  |  |  |  |
Adjustment to Compensation Amount | $ 14,872 | $ 9,325 | $ 3,419 |  |  |  |  |  |  |  |  |  |

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToNonPeoNeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_AdjToPeoCompFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_CoSelectedMeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iii + Details
Name: | ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph ii + Details
Name: | ecd_CompActuallyPaidVsNetIncomeTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph i + Details
Name: | ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_MeasureName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_NamedExecutiveOfficersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph vi + Details
Name: | ecd_NonGaapMeasureDescriptionTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_NonPeoNeoAvgCompActuallyPaidAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_NonPeoNeoAvgTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupIssuersFnTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_PeerGroupTotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iii + Details
Name: | ecd_PeoActuallyPaidCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 3 + Details
Name: | ecd_PeoName
Namespace Prefix: | ecd_
Data Type: | xbrli:normalizedStringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph ii + Details
Name: | ecd_PeoTotalCompAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTable
Namespace Prefix: | ecd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details
Name: | ecd_PvpTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 6 + Details
Name: | ecd_TabularListTableTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 2 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnAmt
Namespace Prefix: | ecd_
Data Type: | xbrli:monetaryItemType
Balance Type: | na
Period Type: | duration

X
- References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 5 -Subparagraph iv + Details
Name: | ecd_TotalShareholderRtnVsPeerGroupTextBlock
Namespace Prefix: | ecd_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Aggregate dividends declared during the period for each share of common stock outstanding. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 + Details
Name: | us-gaap_CommonStockDividendsPerShareDeclared
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 4 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 220 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 40 -Section 65 -Paragraph 1 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 50 -Paragraph 6 -URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 60B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1A -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580 Reference 25: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794 Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 11 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794 Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 7 -URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760 Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 1B -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 + Details
Name: | us-gaap_NetIncomeLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Price of a single share of a number of saleable stocks of a company. + References No definition available. + Details
Name: | us-gaap_SharePrice
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | ecd_MeasureAxis=1
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_PeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=usph_ReportedValueOfStockAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=usph_YearEndFairValueOfRestrictedStockAwardsGrantedDuringTheYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=usph_ChangeInFairValueOfOutstandingAndUnvestedRestrictedStockAwardsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=usph_ChangesInFairValueOfRestrictedStockInPriorYearsThatVestedDuringTheYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_AdjToCompAxis=usph_DividendsPaidOnUnvestedRestrictedStockAwardsDuringTheFiscalYearMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |